Paul Foster is a notable inventor based in Rancho Santa Fe, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibody therapies. With a total of 4 patents to his name, Foster's work has the potential to impact various medical applications.

Latest Patents

Foster's latest patents include groundbreaking inventions such as "Heterodimeric antibodies that bind somatostatin receptor 2." This invention focuses on antibodies that include novel antigen binding domains and heterodimeric antibodies targeting somatostatin receptor 2 (SSTR2). Another significant patent is titled "Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases." This disclosure relates to immunoglobulins that bind FcγRIIb+ B cells and coengage CD19 on the cell's surface, providing methods for their generation and use in treating IgG4-related diseases.

Career Highlights

Paul Foster is currently associated with Xencor, Inc., a company known for its innovative approaches in the field of biopharmaceuticals. His work at Xencor has allowed him to explore and develop advanced therapeutic solutions that address critical health challenges.

Collaborations

Foster collaborates with esteemed colleagues such as Gregory L. Moore and Rumana Rashid. These partnerships enhance the research and development efforts at Xencor, fostering an environment of innovation and discovery.

Conclusion

In summary, Paul Foster is a distinguished inventor whose work in antibody technology is paving the way for new therapeutic options. His contributions to the field are significant and continue to influence advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.